Supplementary protection certificates (SPCs) play an important role in the patent strategies of many companies in the life sciences sector, but a series of European court decisions has given IP in-housers food for thought when looking to obtain SPCs.
Adam Houldsworth
The use of alternative dispute resolution by some SEP owners is growing in India and offers firms an increasingly attractive method of settling IP conflicts in the country.
Pravin Anand, Vaishali Mittal and Siddhant Chamola
In the five years since the US Supreme Court’s decision in Alice Corp v CLS Bank International, patent owners, their advisers, the judiciary and legislators have all struggled to come to terms with its impact. With policymakers currently eyeing possible legislation on Section 101 of the US Patent Statute, the case continues to cast a long shadow on the IP market.
Greg Hopewell, Christopher King and Robert R Sachs
A growing number of studies are attempting to lift the lid on which companies own the most 5G patents, but such reports do not always reveal the full picture.
Matthew Noble, Richard Vary and Jane Mutimear
Generating value from a portfolio does not mean revenue on the balance sheet for the vast majority of patent-owning businesses, so IP leaders must look for other ways to show the value that intellectual property brings to a company.
Richard Lloyd
The IAM/ktMINE US Patent 1,000 counts down every entity that owns at least 1,000 US grants, with breakdowns by country and industry, to reveal the biggest movers.
Megan Rourke and Eric Podlogar
The Supreme Court’s judgment in Alice has had a huge impact on case law governing patent-eligible subject matter in the United States, but it has not had the effect on the secondary deals market that might have been expected.
Michael Costa, Erik Oliver and Kent Richardson
Southeast Asia is home to a thriving high-tech sector, but the patent systems in many of the region’s economies remain in their infancy.
Jacob Schindler
Having been the subject of a key decision from the UK Supreme Court, plausibility has been an increasingly important topic for life sciences rights holders to consider in both patent prosecution and litigation.
Paul England and Matthew Royle
